FDA approves Gilead’s hep C drug Epclusa
The U.S. Food and Drug Administration approved Gilead Sciences Inc’s drug for treating chronic hepatitis C virus infection.
The drug, Epclusa, is approved for use in combination with ribavirin.
Epclusa is the first drug to treat all six major types of hepatitis C virus infection.
Gilead shares were up 4 pct at $81.03 in morning trading on the Nasdaq.
(Reporting by Shailesh Kuber in Bengaluru; Editing by Don Sebastian)
Source: Reuters Health